Heska

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Heska Corporation manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health.

Volitionrx Limited

HENDERSON, Nev. , Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heska (HSKA) Reports Next Week: Wall Street Expects Earnings Growth

LOVELAND, Colo. , Oct. 18, 2022  /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its third quarter 2022 financial performance in a press release before the market opens on Tuesday, November 8, 2022.

Heska Third Quarter 2022 Financial Results and Earnings Call Scheduled for November 8, 2022

LOVELAND, Colo. , Sept. 12, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities (the "Acquisition").

Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts

LOVELAND, Colo. , Aug. 19, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, today released its 2021 Environmental, Social & Governance (ESG) Factsheet, which includes disclosure regarding environmental, workforce, and corporate governance priorities.

Heska Publishes Environmental, Social and Governance (ESG) Factsheet to Share Commitment to Sustainable Responsibilities and Initiatives

Heska Corp (NASDAQ:HSKA ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - CEO, President Catherine Grassman - EVP & CFO Conference Call Participants David Westenberg - Piper Sandler Elliot Wilbur - Raymond James Ben Haynor - Alliance Global Partners Erin Wright - Morgan Stanley Jim Sidoti - Sidoti & Company Operator Good day, ladies and gentlemen, and welcome to the Heska Corporation Second Quarter 2022 Conference Call. Today's conference is being recorded.

Heska Corp (HSKA) CEO Kevin Wilson on Q2 2022 Results - Earnings Call Transcript

Heska (HSKA) delivered earnings and revenue surprises of -8.11% and 6.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Q2 Earnings and Revenues Miss Estimates

Credit Suisse

Las Vegas Sands

Tandem Diabetes Care

Zalando SE

Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio.

5 Toxic Stocks That May Prove Hazardous for Your Portfolio

LOVELAND, Colo. , Aug. 8, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its second quarter ended June 30, 2022.

Heska Corporation Reports Second Quarter 2022 Results

Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for

LOVELAND, Colo. , July 20, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its second quarter 2022 financial performance in a press release before the market opens on Monday, August 8, 2022.

Heska Second Quarter 2022 Financial Results and Earnings Call Scheduled for August 8, 2022

LOVELAND, Colo. , May 25, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced that Kevin Wilson, Heska's President & Chief Executive Officer, will present at the Stifel 2022 Jaws and Paws Conference at the Pierre New York Hotel in New York City on Wednesday, June 1, 2022 at 3:00 p.m.

Heska to Present at the Upcoming Stifel 2022 Jaws and Paws Conference

Heska Corp (NASDAQ:HSKA ) Q1 2022 Earnings Conference Call May 9, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - CEO, President & Director Catherine Grassman - EVP & CFO Conference Call Participants David Westenberg - Piper Sandler & Co. Christopher Schott - JPMorgan Chase & Co. Elliot Wilbur - Raymond James & Associates Benjamin Haynor - Alliance Global Partners James Sidoti - Sidoti & Company Operator Good day, and welcome to the Heska Corporation First Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Heska Corp (HSKA) CEO Kevin Wilson on Q1 2022 Results - Earnings Call Transcript

Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Misses Q1 Earnings and Revenue Estimates

Quarterly Revenue Up 7% (10% in Constant Currency), Gross Margin Up 290 bps North America POC Lab Consumables Up 10%, Full Year Outlook Reiterated LOVELAND, Colo. , May 9, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its first quarter ended March 31, 2022.

Heska Corporation Reports First Quarter 2022 Results

Earnings Preview: Heska (HSKA) Q1 Earnings Expected to Decline

LOVELAND, Colo. , April 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, plans to host its 2022 Investor Day in a virtual format on Tuesday, May 17, 2022 at 9:00 a.m.

Heska to Host Virtual 2022 Investor Day on May 17, 2022

LOVELAND, Colo. , April 18, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its first quarter 2022 financial performance in a press release before the market opens on Monday, May 9, 2022.

Heska First Quarter 2022 Financial Results and Earnings Call Scheduled for May 9, 2022

LOVELAND, Colo. , April 14, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announces its 2022 Annual Meeting of Stockholders.

Heska Announces its Annual Meeting of Stockholders on May 4, 2022

VolitionRx (NYSE-A:VNRX) Ltd has struck an exclusive $28 million deal with veterinary diagnostic firm Heska Corporation to license and sell the former's Nu.Q vet cancer screening test at the point-of-care for pets. Heska will receive the worldwide rights to sell the test while VolitionRx (NYSE-A:VNRX) will get a $10 million upfront payment on signing and up to $18 million based upon near to mid-term milestones.

VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening test

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) ("Heska") to sell its Nu.Q® Vet Cancer Screening Test at the point of care for companion animals. Heska is a leading global provider of advanced veterinary diagnostics.

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

LOVELAND, Colo. , March 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, has announced an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") to adapt and commercialize the Nu.Q® Vet Cancer Screening Test at the point of care for companion animals on Heska's technology.

Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer Screen

Heska Corporation's (HSKA) CEO Kevin Wilson on Q4 2021 Results - Earnings Call Transcript

Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Tops Q4 Earnings and Revenue Estimates

LOVELAND, Colo., Feb. 28, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2021.

News for Heska Stock (HSKA)